Postmenopozal Kadınlarda Tibolon ve İntranasal Östradiol’ün Kan Lipid Parametreleri Üzerine Olan Etkileri
Yükleniyor...
Dosyalar
Tarih
2007
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi Tıp Fakültesi Dergisi
Erişim Hakkı
Attribution 3.0 United States
Özet
Tibolon ve intranasal östrojen replasman tedavisi’nin serum lipid seviyeleri üzerine etkilerinin karşılaştırılması
Gereç ve Yöntem: Çalışmaya toplam 84 postmenopozal kadın dahil edildi. Hastalara günlük tibolon (2,5 mg)(Grup I; n= 35) ve intranasal östrojen (Grup II; n= 49) verildi. Tedavi süresi 6 aydı. Tedavinin başlangıcı ve sonu lipid seviyeleri her grup için ölçüldü ve farklı iki grubun değerleri karşılaştırıldı. İstatistiksel analiz için Student-t testi kullanıldı.
Sonuç: Her iki grup değişkenlerin basal seviyeleri arasında istatistiksel olarak anlamlı fark saptanmadı. Her iki grupta total kolesterol seviyeleri başlangıç seviyelerine göre belirgin artmıştı. Fakat 6 aylık tedavi sonrasında iki grup arasında istatistiksel fark saptanamadı. LDL kolesterol (LDL-C) seviyelerinde her iki grupta da tedavi öncesine göre değişim saptanamadı. HDL kolesterol (HDL-C) seviyeleri intranasal 17β-E2 grubunda belirgin olarak azalırken, tibolon grubunda belirgin olarak artmıştır. Trigliserid (TAG) seviyeleri intranasal 17β-E2 grubunda belirgin azalırken tibolon grubunda belirgin değişiklik saptanmadı. Her iki grup Lipoprotein (a) (Lp(a)) seviyeleri her iki tedavide de değişim saptanmadı.
Tartışma: Postmenopozal kadınlarda, tibolon ile kısa süreli tedavinin iyi klinik-laboratuar güvenlilik profili gösterdiği saptandı.. Ayrıca postmenopozal kadınlarda diğer HRT protokollerine iyi bir alternatif olabilir.
To compare tibolone therapy with intranasal estrogen replacement therapy protocols on their effects on serum lipid profiles. Material Method: 84 post-menopausal women were included in the study. They were given either oral daily treatment with tibolone (2.5 mg) (Group I; n= 35); or intranasal administration of estrogen (Group II; n = 49 ). The duration of the treatment was 6 months. At the beginning and at the end of the therapy, lipid levels were measured in each of the group and then these two different groups were compared. Student-t test was used for statistical analysis. Results: No statistical difference was observed at baseline levels between two groups. Total cholosterol levels were increased significantly from baseline levels in both groups. However, at the end of the 6 months no statistical difference was found between two groups. LDL-cholesterol (LDL-C) levels were not changed from the baseline levels in both of the groups. In intranasal estrogen group, while HDL-C levels were decreased, it has increased in tibolone group. While triglycerides (TAG) levels were significantly decreased in intranasal 17β-E2 group, no significant change has been found in tibolone group. Lp(a) levels were not changed with therapy in both group. Conclusion: Short-term treatment with tibolone showed a good clinical-laboratory safety profile in postmenopausal women. Also it may be a good alternative to other HRT protocols in postmenopausal women.
To compare tibolone therapy with intranasal estrogen replacement therapy protocols on their effects on serum lipid profiles. Material Method: 84 post-menopausal women were included in the study. They were given either oral daily treatment with tibolone (2.5 mg) (Group I; n= 35); or intranasal administration of estrogen (Group II; n = 49 ). The duration of the treatment was 6 months. At the beginning and at the end of the therapy, lipid levels were measured in each of the group and then these two different groups were compared. Student-t test was used for statistical analysis. Results: No statistical difference was observed at baseline levels between two groups. Total cholosterol levels were increased significantly from baseline levels in both groups. However, at the end of the 6 months no statistical difference was found between two groups. LDL-cholesterol (LDL-C) levels were not changed from the baseline levels in both of the groups. In intranasal estrogen group, while HDL-C levels were decreased, it has increased in tibolone group. While triglycerides (TAG) levels were significantly decreased in intranasal 17β-E2 group, no significant change has been found in tibolone group. Lp(a) levels were not changed with therapy in both group. Conclusion: Short-term treatment with tibolone showed a good clinical-laboratory safety profile in postmenopausal women. Also it may be a good alternative to other HRT protocols in postmenopausal women.
Açıklama
İnönü Üniversitesi Tıp Fakültesi Dergisi
14(3) 157-161 (2007)
Anahtar Kelimeler
Tibolon, İntranasal östrojen, Lipidler, Tibolone, İntranasal estrogen, Lipids
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Kaplanoğlu, Mustafa ; Kıran, Hakan ;Kıran, Gürkan ;İnönü Üniversitesi Tıp Fakültesi Dergisi 14(3) 157-161 (2007)
